In vivo and in vitro estrogenic activity of the antidepressant fluoxetine

Reproductive Toxicology

Volumn 34, Issue 1, 2012, Pages 80-85

  Müller, Juliane C ^a   Imazaki, Pedro H ^b   Boareto, Ana C ^a   Lourenço, Emerson L B ^a   Golin, Munisa ^a   Vechi, Marina F ^a   Lombardi, Natália F ^a   Minatovicz, Bruna C ^a   Scippo, Marie Louise ^b   Martino Andrade, Anderson J ^a   Dalsenter, Paulo R ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Depression; Endocrine disruption; Estrogenic activity; Fluoxetine; Hershberger assay; Reporter gene assay; Uterotrophic assay

Indexed keywords

ANDROGEN; ESTRADIOL; FLUOXETINE; TESTOSTERONE;

ANDROGENIC ACTION; ANIMAL EXPERIMENT; ANTIANDROGENIC ACTION; ANTIESTROGENIC ACTION; ARTICLE; ASSAY; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ESTROGENIC ACTIVITY; GENETIC TRANSFECTION; HERSHBERGER ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; REPORTER GENE; UTERUS WEIGHT; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CELL LINE, TUMOR; ESTROGENS, NON-STEROIDAL; FEMALE; FLUOXETINE; GENITALIA, MALE; HUMANS; MALE; ORGAN SIZE; RATS; RATS, WISTAR; RECEPTORS, ESTROGEN; UTERUS;

RATTUS;

EID: 84861688839     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2012.04.001     Document Type: Article

References (64)

1. Kessler R.C., McGonagle K.A., Nelson C.B., Hughes M., Swartz M., Blazer D.G. Sex and depression in the National Comorbidity Survey: II. Cohort effects. Journal of Affective Disorders 1999, 30:15-26.
2. Marcus S.M., Flynn H.A., Blow F.C., Barry K.L. Depressive symptoms among pregnant women screened in obstetrics settings. Journal of Women's Health 2003, 12:373-380.
3. Bennett H.A., Einarson A., Taddio A., Koren G., Einarson T.R. Prevalence of depression during pregnancy: systematic review. Obstetrics and Gynecology 2004, 103:698-709.
4. Moraes I., Pinheiro R.T., Silva R.A., Horta B.L., Sousa P.L., Faria A.D. Prevalence of postpartum depression and associated factors. Revista Saude Publica 2006, 40:65-70.
5. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder 2010, American Psychiatric Association, Washington DC, http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx [accessed 20.06.11]. 3rd ed.
6. Altshuler L.L., Cohen L., Szuba M.P., Burt V.K., Gitlin M., Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. American Journal of Psychiatry 1996, 153:592-606.
7. McConnell P.J., Linn K., Filkins K. Depression and pregnancy: use of selective serotonina reuptake inhibitors in pregnancy. Primary Care Update Obstetrics and Gynecology 1998, 5:11-15.
8. Cooper W.O., Willy M.E., Pont S.J., Ray W.A. Increasing use of antidepressants in pregnancy. American Journal of Obstetrics and Gynecology 2007, 196(544):e1-e5.
9. Andrade S.E., Raebel M.A., Brown J., Lane K., Livingston J., Boudreau D., et al. Use of antidepressant medications during pregnancy: a multisite study. American Journal of Obstetrics and Gynecology 2008, 198(194):e1-e5.
10. Fong P.P., Huminski P.T., D'Urso L.M. Induction and potentiation of parturition in fingernail clams (Sphaerium striatinum) by selective serotonin re-uptake inhibitors (SSRIs). Journal of Experimental Zoology 1998, 280:260-264.
11. Flaherty C.M., Kashian D.R., Dodson S.I. Ecological impacts of pharmaceuticals on zooplankton: the effects of three medications on Daphnia magna. Annual Meeting of the Society of Environmental Toxicology and Chemistry 2001.
12. Brooks B.W., Foran C.M., Richards S.M., Weston J., Turner P.K., Stanley J.K., et al. Aquatic ecotoxicology of fluoxetine. Toxicology Letters 2003, 142:169-183.
13. Brooks B.W., Turner P.K., Stanley J.K., Weston J.J., Glidewell E.A., Foran C.M., et al. Waterborne and sediment toxicity of fluoxetine to select organisms. Chemosphere 2003, 52:135-142.
14. Foran C.M., Weston J., Slattery M., Brooks B.W., Huggett D.B. Reproductive assessment of Japanese medaka (Oryzias latipes) following a four-week fluoxetine (SSRI) exposure. Archives of Environment Contamination and Toxicology 2004, 46:511-517.
15. Gust M., Buronfosse T., Giamberini L., Ramil M., Mons R., Garric J. Effects of fluoxetine on the reproduction of two prosobranch mollusks: Potamopyrgus antipodarum and Valvata piscinalis. Environmental Pollution 2009, 157:423-429.
16. Lister A., Regan C., Van Zwol J., Van Der Kraak G. Inhibition of egg production in zebrafish by fluoxetine and municipal effluents: a mechanistic evaluation. Aquatic Toxicology 2009, 95:320-329.
17. Mennigen J.A., Lado W.E., Zamora J.M., Duarte-Guterman P., Langlois V.S., Metcalfe C.D., et al. Waterborne fluoxetine disrupts the reproductive axis in sexually mature male goldfish, Carassius auratus. Aquatic Toxicology 2010, 100:354-364.
18. Fong P.P. Zebra mussel spawning is induced in low concentrations of putative serotonin reuptake inhibitors. Biological Bulletin 1998, 194:143-149.
19. Sánchez-Argüello P., Fernández C., Tarazona J.V. Assessing the effects of fluoxetine on Physa acuta (Gastropoda, Pulmonata) and Chironomus riparius (Insecta, Diptera) using a two-species water-sediment test. Science of the Total Environment 2009, 407:1937-1946.
20. Henry T.B., Black M.C. Acute and chronic toxicity of fluoxetine (selective serotonin reuptake inhibitor) in western mosquitofish. Archives of Environment Contamination and Toxicology 2008, 54:325-330.
21. Matuszczyk J.V., Larsson K., Eriksson E. Subchronic administration of fluoxetine impairs estrous behavior in intact female rats. Neuropsychopharmacology 1998, 19:492-498.
22. Uphouse L., Hensler J.G., Sarkar J., Grossie B. Fluoxetine disrupts food intake and estrous cyclicity in Fischer female rats. Brain Research 2006, 1072:79-90.
23. Maswood N., Sarkar J., Uphouse L. Modest effects of repeated fluoxetine on estrous cyclicity and sexual behavior in Sprague Dawley female rats. Brain Research 2008, 1245:52-60.
24. Taylor G.T., Farr S., Klinga K., Weiss J. Chronic fluoxetine suppresses circulating estrogen and the enhanced spatial learning of estrogen-treated ovariectomized rats. Psychoneuroendocrinology 2004, 29:1241-1249.
25. Tabacova S. Fluoxetine developmental toxicity: animal-to-human comparisons 2001, National Center for Toxicological Research, Washington, DC.
26. Bauer S., Monk C., Ansorge M., Gyamfi C., Myers M. Impact of antenatal selective serotonin reuptake inhibitor exposure on pregnancy outcomes in mice. American Journal of Obstetrics and Gynecology 2010, 203(375):e1-e4.
27. Hoyt J., Byrd R., Brophy G., Markham J. A reproduction study of fluoxetine hydrochloride (I) administered in the diet to rats. Teratology 1989, 39:459.
28. Silva J.V.A., Lins A.M.J.A.A., Amorim J.A.A., Pinto C.F., Deiró T.B.J., Oliveira J.R.M., et al. Neonatal administration of fluoxetine decreased final sertoli cell number in Wistar rats. International Journal of Morphology 2008, 26:51-62.
29. Simon G.E., Cunningham M.L., Davis R.L. Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry 2002, 159:2055-2061.
30. National Toxicology Program, Center for the Evaluation of Risks to Human Reproduction. Expert panel report on the reproductive and developmental toxicity of fluoxetine. Research Triangle Park NC: National Toxicology Program, Center for the Evaluation of Risks to Human Reproduction; 2003. ; [accessed 20.06.11]. http://cerhr.niehs.nih.gov/chemicals/fluoxetine/fluoxetine_final.pdf.
31. Strain S.L. Fluoxetine-initiated ovulatory cycles in two clomiphene-resistant women. American Journal of Psychiatry 1994, 151:620.
32. Warnock J.K., Clayton A.H., Shaw H.A., O'Donnell T. Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine. Psychopharmacology Bulletin 1995, 31:239-242.
33. Iancu I., Ratzoni G., Weitzman A., Apter A. More fluoxetine experience. Journal of the American Academy of Child and Adolescent Psychiatry 1992, 31:755-756.
34. Arya D.K., Taylor W.S. Lactation associated with fluoxetine treatment. Australian and New Zealand Journal of Psychiatry 1995, 29:697.
35. Egberts A.C., Meyboom R.H., De Koning F.H., Bakker A., Leufkens H.G. Non-puerperal lactation associated with antidepressant drug use. British Journal of Clinical Pharmacology 1997, 44:277-281.
36. Menkes D.B., Taghavi E., Mason P.A., Howard R.C. Fluoxetine's spectrum of action in premenstrual syndrome. International Clinical Psychopharmacology 1993, 8:95-102.
37. Steiner M., Lamont J., Steinberg S., Stewart D., Reid R., Streiner D. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. Obstetrics and Gynecology 1997, 90:590-595.
38. Safarinejad M.R. Sperm DNA damage and semen quality impairment after treatment with selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure assay. Journal of Urology 2008, 180:2124-2128.
39. Safarinejad M.R. Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction. Journal of Clinical Psychopharmacology 2008, 28:418-423.
40. Cooke P.S., Peterson R.E., Hess R.A. Endocrine disruptors. Handbook of toxicologic pathology 2002, 501-529. Academic Press, San Diego:. 2nd ed. W.M. Haschek, C.G. Rosseaux, M.A. Wallig (Eds.).
41. Environmental Protection Agency. Guidelines for reproductive toxicity risk assessment. EPA/630/R-96/009. Washington DC: Environmental Protection Agency; 1996. ; [accessed 20.06.11]. http://www.epa.gov/raf/publications/pdfs/REPRO51.PDF.
42. Environmental Protection Agency. Special report on environmental endocrine disruption: an effects assessment and analysis [report no. EPA/630/R-96/012]. Washington DC: Environmental Protection Agency; 1997. ; [accessed 20.06.11]. http://www.epa.gov/raf/publications/pdfs/ENDOCRINE.PDF.
43. Organisation for Economic Co-operation and Development. Workshop report on OECD countries activities regarding testing, assessment and management of endocrine disrupters, Appendices 1-10, Part II. Paris: Organisation for Economic Co-operation and Development; 2010. ; [accessed 20.06.11]. http://www.oecd.org/dataoecd/26/22/44431552.pdf.
44. Cohen L.S., Rosenbaum J.F. Psychotropic drug use during pregnancy: weighing the risks. Journal of Clinical Psychiatry 1998, 59(Suppl 2):18-28.
45. American Academy of Pediatrics, Committee on Drugs Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics 2000, 105:880-887.
46. Kanno J., Onyon L., Haseman J., Fenner-Crisp P., Ashby J., Owens W. The OECD program to validate the rat uterotrophic bioassay to screen compounds for in vivo estrogenic responses: phase 1. Environmental Health Perspectives 2001, 109:785-794.
47. Organisation for Economic Co-operation and Development. Draft report of the OECD validation of the rat Hershberger bioassay: Phase 3. Coded testing of androgen agonists, androgen antagonists and negative reference chemicals by multiple laboratories. Surgical castrate model protocol. Paris: Organisation for Economic Co-operation and Development; 2006. ; [accessed 20.06.11]. http://www.epa.gov/endo/pubs/hershberger_phase3_report.pdf.
48. Organisation for Economic Cooperation and Development OECD guideline for the testing of chemicals. Uterotrophic bioassay in rodents: a short-term screening test for oestrogenic properties 2007, Organisation for Economic Cooperation and Development, Paris, http://www.epa.gov/endo/pubs/uterotrophic_OECD_guideline.pdf; [accessed 20.06.11].
49. Nevill A.M. The need to scale for differences in body size and mass: an explanation of Kleiber's 0.75 mass exponent. Journal of Applied Physiology 1994, 77:2870-2873.
50. American Veterinary Medical Association. Guidelines on euthanasia [formerly report of the AVMA Panel on Euthanasia]. Schaumburg IL: American Veterinary Medical Association; 2007. ; [accessed 20.06.11]. http://www.avma.org/issues/animal_welfare/euthanasia.pdf.
51. Willemsen P., Scippo M.L., Kausel G., Figueroa J., Maghuin-Rogister G., Martial J.A., et al. Use of reporter cell lines for detection of endocrine-disrupter activity. Analytical and Bioanalytical Chemistry 2004, 378:655-663.
52. Reel J.R., Lamb J.C., Neal B.H. Survey and assessment of mammalian estrogen biological assays for hazard characterization. Fundamental and Applied Toxicology 1996, 34:288-305.
53. Shelby M.D., Newbold R.R., Tully D.B., Chae K., Davis V.L. Assessing environmental chemicals for estrogenicity using a combination of in vitro and in vivo assays. Environmental Health Perspectives 1996, 104:1296-1300.
54. Jones R.C., Edgren R.A. The effects of various steroids on the vaginal histology in the rat. Fertility and Sterility 1973, 24:284-291.
55. Korach K.S., McLachlan J.A. Techniques for detection of oestrogenicity. Environmental Health Perspectives 1995, 103(Suppl 7):5-8.
56. Raap D.K., Van de Kar L.D. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sciences 1999, 65:1217-1235.
57. Parks L.G., Ostby J.S., Lambright C.R., Abbott B.D., Klinefelter G.R., Barlow N.J., et al. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. Toxicological Sciences 2000, 58:339-349.
58. Stroheker T., Cabaton N., Nourdin G., Regnier J.F., Lhuguenot J.C., Chagnon M.C. Evaluation of anti-androgenic activity of di-(2-ethylhexyl)phthalate. Toxicology 2005, 208:115-121.
59. Morford L.L., Henck J.W., Breslin W.J., DeSesso J.M. Hazard identification and predictability of children's health risk from animal data. Environmental Health Perspectives 2004, 112:266-271.
60. Louis G.M., Cooney M.A., Lynch C.D., Handal A. Periconception window: advising the pregnancy-planning couple. Fertility and Sterility 2008, 89(2 Suppl):e119-e121.
61. Woodruff T.J., Carlson A., Schwartz J.M., Giudice L.C. Proceedings of the summit on environmental challenges to reproductive health and fertility: executive summary. Fertility and Sterility 2008, 89:281-300.
62. Heikkine T., Ekblad U., Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG: an International Journal of Obstetrics and Gynaecology 2002, 109:1003-1008.
63. Hendrick V., Stowe Z.N., Altshuler L.L., Mintz J., Hwang S., Hostetter A., et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. Biological Psychiatry 2001, 50:775-782.
64. Suri R., Stowe Z.N., Hendrick V., Hostetter A., Widawski M., Altshuler L.L. Estimates of nursing infant daily dose of fluoxetine through breast milk. Biological Psychiatry 2002, 52:446-451.